These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 31287991)

  • 41. Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data.
    Guo GF; Wang YX; Zhang YJ; Chen XX; Lu JB; Wang HH; Jiang C; Qiu HQ; Xia LP
    World J Gastroenterol; 2019 Apr; 25(15):1840-1853. PubMed ID: 31057298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A
    Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer.
    Chen W; Liao Y; Yang C; Fang Z; Liu B; Zheng X; Zhou C
    Biomarkers; 2019 Sep; 24(6):524-529. PubMed ID: 31220949
    [No Abstract]   [Full Text] [Related]  

  • 44. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.
    Nakajima TE; Boku N; Doi A; Arai H; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y
    Invest New Drugs; 2020 Apr; 38(2):410-418. PubMed ID: 31020609
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.
    Luraghi P; Bigatto V; Cipriano E; Reato G; Orzan F; Sassi F; De Bacco F; Isella C; Bellomo SE; Medico E; Comoglio PM; Bertotti A; Trusolino L; Boccaccio C
    Clin Cancer Res; 2018 Feb; 24(4):807-820. PubMed ID: 28974546
    [No Abstract]   [Full Text] [Related]  

  • 47. Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.
    Arena S; Bellosillo B; Siravegna G; Martínez A; Cañadas I; Lazzari L; Ferruz N; Russo M; Misale S; González I; Iglesias M; Gavilan E; Corti G; Hobor S; Crisafulli G; Salido M; Sánchez J; Dalmases A; Bellmunt J; De Fabritiis G; Rovira A; Di Nicolantonio F; Albanell J; Bardelli A; Montagut C
    Clin Cancer Res; 2015 May; 21(9):2157-66. PubMed ID: 25623215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
    Dercle L; Lu L; Schwartz LH; Qian M; Tejpar S; Eggleton P; Zhao B; Piessevaux H
    J Natl Cancer Inst; 2020 Sep; 112(9):902-912. PubMed ID: 32016387
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.
    Woolston A; Barber LJ; Griffiths B; Pich O; Lopez-Bigas N; Matthews N; Rao S; Watkins D; Chau I; Starling N; Cunningham D; Gerlinger M
    Nat Ecol Evol; 2021 Jul; 5(7):1024-1032. PubMed ID: 34017094
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.
    Ito Y; Yamada Y; Asada K; Ushijima T; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1391-6. PubMed ID: 23722667
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcriptome Alterations in Liver Metastases of Colorectal Cancer After Acquired Resistance to Cetuximab.
    Li Z; Chen Y; Ren WU; Hu S; Tan Z; Wang Y; Chen Y; Zhang J; Wu J; Li T; Xu J; Ying X
    Cancer Genomics Proteomics; 2019; 16(3):207-219. PubMed ID: 31018951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inactivation of
    Georgiou A; Stewart A; Cunningham D; Banerji U; Whittaker SR
    Mol Cancer Res; 2020 Jun; 18(6):835-846. PubMed ID: 32098826
    [TBL] [Abstract][Full Text] [Related]  

  • 54. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
    Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
    Lièvre A; Ouine B; Canet J; Cartier A; Amar Y; Cacheux W; Mariani O; Guimbaud R; Selves J; Lecomte T; Guyetant S; Bieche I; Berger F; de Koning L
    Br J Cancer; 2017 Dec; 117(12):1819-1827. PubMed ID: 29024937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
    Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
    Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
    Van Emburgh BO; Arena S; Siravegna G; Lazzari L; Crisafulli G; Corti G; Mussolin B; Baldi F; Buscarino M; Bartolini A; Valtorta E; Vidal J; Bellosillo B; Germano G; Pietrantonio F; Ponzetti A; Albanell J; Siena S; Sartore-Bianchi A; Di Nicolantonio F; Montagut C; Bardelli A
    Nat Commun; 2016 Dec; 7():13665. PubMed ID: 27929064
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
    Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
    Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.